Clinical trials: Influenza Vaccines
Influenza
Safety and Immunogenicity Study of Fluval AB-Like Flu Vaccines With 3.5, 6, 9 or 15 μg HA in Adult and Elderly People
The purpose of this study is to determine the immunogenicity, tolerability and dose-effect relationship of one 0.5 mL intramuscular (IM) injection of four FLUVAL AB-like trivalent influenza vaccines containing either 3.5μgHA…
- Trial name
- NCT01408290
- Testing
- Vaccination with FAB-3511, Vaccination with FAB-6011, Vaccination with FAB-9011
- Where
- 4 sites in Hungary
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications
The purpose of this study is to evaluate the effectiveness of CD388 in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, and to select a dose of CD388 that is effective in preventing the…
- Trial name
- NAVIGATE (NCT06609460)
- Testing
- CD388 Injection
- Where
- 57 sites in United States, United Kingdom
- Volunteers
- 5,071 people, healthy volunteers welcome
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Influenza
Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline Biologicals' seasonal influenza vaccine, Fluarix, compared to Fluzone (a US-licensed vaccine) in children, 6 to 35 months of age.
- Trial name
- NCT00764790
- Testing
- Fluarix, Fluzone
- Where
- 69 sites in United States, Hong Kong and 3 more
- Volunteers
- 3,317 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray
This study is being conducted to assess the safety, tolerability, and immunogenicity of the live-attenuated CodaVax-H1N1 influenza vaccine as compared to normal saline placebo both administered via intranasal spray to healthy…
- Trial name
- NCT04146623
- Testing
- CodaVax-H1N1 influenza vaccine
- Where
- Australia
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Codagenix, Inc
Influenza
Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine
As a result of the recent supply shortages in the U.S., as well as an anticipated increase in demand during the coming years, GSK Biologicals is pursuing licensure of Fluarix in the U.S.
- Trial name
- NCT00197223
- Testing
- Influenza vaccine
- Where
- Czechia
- Volunteers
- 6,213 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immunization
Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants
The purpose of this study is to evaluate the safety and efficacy of an intramuscular injection of BK1310 in healthy infants.
- Trial name
- NCT03188692
- Testing
- DPT-IPV-Hib (Combined Vaccine)
- Where
- 3 sites in Japan
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Influenza
Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)
To assess the safety of a vaccine in healthy adults prior to the release of the trivalent vaccine (FluMist).
- Trial name
- NCT00240877
- Testing
- AV024
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Pandemic
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults
The purpose of this clinical trial is to evaluate the safety and immunogenicity of BW-1014. BW-1014 is a nanoemulsion (NE) adjuvanted recombinant Hemagglutinin 5 (rH5) that would protect against pandemic flu.
- Trial name
- IN-NE-rH5 (NCT05397119)
- Testing
- BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- BlueWillow Biologics
Respiratory Infection Virus, COVID-19
Noseguard for Prevention of Respiratory Infections in Real-World Use
This study is a prospective clinical study to evaluate the effectiveness of combined use of two nasal protective medical devices (Noseguard and Noseguard Night) in reducing respiratory infection rates, including COVID-19 and…
- Conditions
- Respiratory Infection Virus, COVID-19, Influenza
- Trial name
- NCT07516977
- Testing
- Noseguard and Noseguard Night
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Epidemic Influenza
Phase IIaTrials of GanMaoKangNing Granules
Randomized, double-blind, double- simulation, positive drug-and-Placebo-Controlled, multicenter, phase IIa clinical trials Study about GanMaoKangNing Granules in improving the symptoms of influenza.
- Trial name
- NCT02989012
- Testing
- GanMaoKangNing Granules, Analogous Oseltamivir Phosphate Capsules, Oseltamivir Phosphate Capsules
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Dalian Zhen-Ao Bio-Tech Co., Ltd.
SARS-CoV2 Infection, Influenza A
Clinical Performance Study for EDAN's COVID-19/Flu A/Flu B/RSV Test Kits on Subjects Suspected of Respiratory Infection
The primary objective of this clinical performance study is to evaluate and further validate the clinical performance of: 1. ClariLight Influenza A/B \& SARS-CoV-2 test kits and 2.
- Conditions
- SARS-CoV2 Infection, Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT06175611
- Testing
- COVID-19/Flu A/Flu B/RSV Test Kit
- Where
- 3 sites in Spain
- Volunteers
- 1,000 people
- Sponsor
- EDAN Instruments Inc.
Influenza
A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension
This study will evaluate the safety, efficacy and pharmacokinetics of Suraxavir Marboxil compared with oseltamivir in Pediatric Patients (2 to <12 Years) with Uncomplicated Influenza.
- Trial name
- NCT07113392
- Testing
- Suraxavir Marboxil, Oseltamivir
- Volunteers
- 144 people
- Sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.
Influenza Caused by the Novel Influenza A (H1N1) Virus
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults
The purpose of the study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults.
- Trial name
- NCT00938639
- Testing
- CSL425
- Where
- Australia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects
The present study will evaluate clinical efficacy, safety, tolerability and immunogenicity of both Novartis Vaccines' cell-derived influenza vaccine and egg-derived influenza vaccine in healthy adults 18 to 49 years of age.
- Trial name
- NCT00630331
- Testing
- Cell culture-derived influenza vaccine, Egg-derived influenza virus vaccine
- Where
- 56 sites in United States, Finland and 1 more
- Volunteers
- 11,404 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pandemic Influenza A (H1N1), A New Flu Virus of Swine Origin
Observational Safety Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine
This is an observational safety study of a prophylactic use of Flu Egg Derived Adjuvanted Swine Origin A(H1N1) Vaccine in subjects 6 months of age and older.
- Trial name
- NCT01040741
- Testing
- Non-intervention observational study
- Where
- 14 sites in Argentina, Netherlands
- Volunteers
- 7,284 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
COVID-19, Influenza A
Performance Evaluation of LumiraDx SARS-CoV-2, Flu A/B, and RSV Tests for COVID-19 Assessment
A Multicenter Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 \& FLU A/B Test, and LumiraDx SARS-CoV-2 \& RSV Test at Point of Care Testing Sites.
- Conditions
- COVID-19, Influenza A, Influenza Type B, RSV Infection
- Trial name
- INSPIRE-2 (NCT05268939)
- Testing
- LumiraDx SARS-CoV-2 & Flu A/B test, LumiraDx SARS-CoV-2 & RSV test
- Where
- 8 sites in United States
- Volunteers
- 589 people
- Sponsor
- LumiraDx UK Limited
Influenza
Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)
This is a multi-center, randomized, two stage, double-blind, placebo-controlled administration study comprising 200 healthy participants.
- Trial name
- NCT01146119
- Testing
- Multimeric-001, 500 mcg, Adjuvanted PBS, PBS and TIV 15%
- Where
- 2 sites in Israel
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Influenza
Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age
The primary objective of the study was to compare the clinical efficacy of high-dose quadrivalent influenza vaccine (QIV-HD) to standard-dose quadrivalent influenza vaccine (QIV-SD) in participants 6 months through 35 months of…
- Trial name
- QHD00014 (NCT04544267)
- Testing
- Quadrivalent influenza vaccine, high-dose, Quadrivalent influenza vaccine, standard dose
- Where
- 10 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza -Like Illness, Influenza A
Home Testing of Respiratory Illness
The main goal of this research study is to use data from activity trackers (such as Fitbits), lab tests, and surveys to see if activity, sleep, and heart rate data can tell the difference between when someone has a respiratory…
- Conditions
- Influenza -Like Illness, Influenza A, Influenza Type B, Respiratory Viral Infection
- Trial name
- NCT04245800
- Where
- United States
- Volunteers
- 5,233 people, healthy volunteers welcome
- Sponsor
- Evidation Health
Influenza, Human
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2015/2016 Quadrivalent Influenza Vaccine…
- Trial name
- NCT02545543
- Testing
- Seqirus QIV, Comparator QIV
- Where
- 32 sites in United States
- Volunteers
- 2,278 people, healthy volunteers welcome
- Sponsor
- Seqirus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.